Skip to main content
Journal cover image

Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.

Publication ,  Journal Article
Armstrong, PW; Adams, PX; Al-Khalidi, HR; Hamm, C; Holmes, D; O'Neill, W; Todaro, TG; Vahanian, A; Van de Werf, F; Granger, CB ...
Published in: Am Heart J
March 2005

Duke Scholars

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

March 2005

Volume

149

Issue

3

Start / End Page

402 / 407

Location

United States

Related Subject Headings

  • Survival Rate
  • Single-Chain Antibodies
  • Shock, Cardiogenic
  • Research Design
  • Randomized Controlled Trials as Topic
  • Premedication
  • Myocardial Infarction
  • Multicenter Studies as Topic
  • Injections, Intravenous
  • Infusions, Intravenous
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Armstrong, P. W., Adams, P. X., Al-Khalidi, H. R., Hamm, C., Holmes, D., O’Neill, W., … APEX-AMI Steering Committee, . (2005). Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J, 149(3), 402–407. https://doi.org/10.1016/j.ahj.2004.12.015
Armstrong, Paul W., Peter X. Adams, Hussein R. Al-Khalidi, Christian Hamm, David Holmes, William O’Neill, Thomas G. Todaro, et al. “Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention.Am Heart J 149, no. 3 (March 2005): 402–7. https://doi.org/10.1016/j.ahj.2004.12.015.
Armstrong PW, Adams PX, Al-Khalidi HR, Hamm C, Holmes D, O’Neill W, Todaro TG, Vahanian A, Van de Werf F, Granger CB, APEX-AMI Steering Committee. Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI): a multicenter, randomized, double-blind, parallel-group, placebo-controlled study of pexelizumab in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention. Am Heart J. 2005 Mar;149(3):402–407.
Journal cover image

Published In

Am Heart J

DOI

EISSN

1097-6744

Publication Date

March 2005

Volume

149

Issue

3

Start / End Page

402 / 407

Location

United States

Related Subject Headings

  • Survival Rate
  • Single-Chain Antibodies
  • Shock, Cardiogenic
  • Research Design
  • Randomized Controlled Trials as Topic
  • Premedication
  • Myocardial Infarction
  • Multicenter Studies as Topic
  • Injections, Intravenous
  • Infusions, Intravenous